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Neuronal cell death, in neurodegenerative disorders, is mediated through a spectrum of biological
processes. Excessive amounts of free radicals, such as reactive oxygen species (ROS), has detrimental
effects on neurons leading to cell damage via peroxidation of unsaturated fatty acids in the cell mem-
brane. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) has been used for neurological recovery in
several countries, including Japan and China, and it has been suggested that Edaravone may have
cytoprotective effects in neurodegeneration. Edaravone protects nerve cells in the brain by reducing ROS
and inhibiting apoptosis. To gain further insight into the cytoprotective effects of Edaravone against
oxidative stress condition we have performed comparative two-dimensional gel electrophoresis (2DE)-
based proteomic analyses on SH-SY5Y neuroblastoma cells exposed to oxidative stress and in combi-
nation with Edaravone. We showed that Edaravone can reverse the cytotoxic effects of H2O2 through its
speciﬁc mechanism. We observed that oxidative stress changes metabolic pathways and cytoskeletal
integrity. Edaravone seems to reverse the H2O2-mediated effects at both the cellular and protein level via
induction of Peroxiredoxin-2.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Neurodegeneration is characterized by the progressive death of
neurons. Neurodegenerative processes cause many neurodegener-
ative disorders including Parkinson's disease (PD), Amyotrophic
lateral sclerosis (ALS), Huntington's disease (HD), and Alzheimer's
diseases (AD). For instance, PD is the most common neurodegen-
erative movement disorder, which affects approximately 1% of in-





(T.A. Neubert), jpl@sus.noneuronal loss (De Lau and Breteler, 2006). Due to the increase in the
aging population the prevalence of PD is very likely to double
within the next two decades (Dorsey et al., 2007). The preferential
dopaminergic neuronal cell death in the substantia nigra results in
reduced dopamine levels in the striatum, which causes the motor
symptoms associated with PD. At clinical diagnosis this region of
the brain has irreversibly lost 50e70% of its neurons compared to
unaffected individuals (Davie, 2008).
Free radicals, like reactive oxygen species (ROS), play a crucial
role in neurodegeneration and brain injury by exacerbating
neuronal cell membrane damage via peroxidation of unsaturated
fatty acids. Since the substantia nigra of PD patients exhibit higher
levels of oxidized lipids (Bosco et al., 2006), proteins and DNA
(Nakabeppu et al., 2007), and lower levels of reduced glutathione
(GSH) (Zeevalk et al., n.d.), oxidative stress and mitochondrial
dysfunction are known to be potential integrated causes of neu-
rodegeneration in PD (Dawson et al., 2010).
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degenerative disease treatment targets, the only current symp-
tomatic approach for treating PD is based on a dopamine
replacement strategy, using the dopamine precursor L-3,4-
dihydroxyphenylalanine (L-Dopa), which at best only alleviates
the motor symptoms. It is known that L-Dopa can also damage
dopaminergic (DA) neurons (Blessing et al., 2003; Mena et al.,
2009) as chronic treatment is associated with the development of
complications such as dyskinesia, motor ﬂuctuation, and dementia
(Liu et al., 2014).
Recently a number of studies have focused on developing
alternative neuroprotective therapeutic approaches with the ulti-
mate aim of potentially slowing down neurodegeneration. In
several countries, including Japan and China, Edaravone (3-methyl-
1-phenyl-2-pyrazolin-5-one) has been widely used during the last
decade for neurological recovery following acute brain ischemia
and subsequent cerebral infarction (Lapchak, 2010). This neuro-
protective drug acts as a potent antioxidant protecting against
oxidative stress and neuronal apoptosis (Kikuchi et al., 2011;
Yoshida et al., 2006) and its beneﬁcial effects has been studied in
several clinical trials (Kikuchi et al., 2014). Indeed it has been shown
that oxidative cell damage in rat brain is reduced by repeated
Edaravone treatment (Yamamoto et al., 2009). Moreover, other
studies on HT22 cells demonstrated that Edaravone protects
against H2O2-induced injury by inhibiting the production of ROS
and activating the MAPK signaling pathway (Zhao et al., 2013).
Edaravone has lipophilic groups, exhibiting good cell membrane
permeability and the ability to cross the bloodebrain barrier.
Recent studies show that Edaravone protects brain nerve cells by
reducing ROS, inhibiting apoptosis, blocking non-enzymatic per-
oxidation and lipoxygenase activity, and preventing vascular
endothelial cell injury (Shinohara and Inoue, 2013). These ﬁndings
suggest that Edaravone may have value in the treatment of
neurodegenerative disorders such as PD.
In our previous study we performed a comparative two-
dimensional gel electrophoresis (2DE)-based proteomic analysis
to gain further insight into the effects of L-DOPA in response to
H2O2-mediated oxidative stress in SH-SY5Y neuronal cells. We
showed that exposure to L-DOPA may aid hypoxia condition in cells
and therefore induction of ORP150 (hypoxia up-regulated protein
1) with its concomitant cytoprotective effects (Jami et al., 2014b).
Here we have performed a similar study to analyze the cytopro-
tective effects of Edaravone. We have shown that similar to L-DOPA,
Edaravone can reverse the cytotoxic effects of H2O2 but through a
different mechanism.
2. Material and methods
2.1. Reagents and cell culture
Fetal bovine serum (FBS), phosphate buffered saline (PBS),
Dulbecco's minimum essential medium plus F12 (DMEM/F12),
penicillin and streptomycin were purchased from Invitrogen (Gai-
thersburg, MD). Acrylamide/bis-acrylamide, tris base, glycine,
ammonium persulfate, PVDF membrane, TEMED, DTT, SDS, urea,
thiourea, glycerol, ammonium bicarbonate, DMSO, ECL reagent,
bromoplenol blue were purchased from Fisher Scientiﬁc (Pitts-
burgh, PA). Trypsin and trypan blue were obtained from Sigma-
eAldrich (St. Louis, MO).
SH-SY5Y cells were cultured in DMEM/F12 containing 10% FBS,
100 U/ml penicillin and 100 mg/ml streptomycin at 37 C in an
atmosphere containing 5% CO2. In order to perform treatments the
media were supplemented with 2 mM H2O2 (SigmaeAldrich, MO),
25 mM Edaravone (Abcam, MA) or a combination of H2O2/Edar-
avone for 8 h (Kaste et al., 2013).2.2. Lactate dehydrogenase (LDH) cytotoxicity assay
Cellular damage following each treatment condition was
assessed by measurement of LDH released into the medium. At the
end (8 h) of each treatment, 50 ml of medium was collected and
transferred to a 96-well plate. The measurement of LDH reaction
level was performed using the Pierce LDH Cytotoxicity Assay Kit
(Thermo Scientiﬁc, USA) following the manufacturer's instructions.
The experiment was performed in three biological and two tech-
nical replicates. The average LDH release values obtained from the
control condition was set to 100% and the relative LDH release
levels for each treatment condition was compared to the control
condition (p < 0.05).
2.3. Apoptosis
The rate of apoptosis in each treatment conditionwas measured
using the TUNEL assay (Dead End Fluorimetric Kit, Promega, USA)
following the manufacturer's instruction. The TUNEL positive cells
(FITC) were counted in the growth plate zones as a percentage of all
cells (FITC and DAPI) in each zone. The average percentage of
TUNEL positive cells in each condition was obtained from 10
different zones under ﬂuorescent microscope and data were
analyzed using One Way ANOVA statistical test.
2.4. Protein sample preparation and 2-DE gel electrophoresis
Protein sample preparation and 2-DE gel electrophoresis were
performed as described before (Jami et al., 2014b). Triplicate
batches of SH-SY5Y cells were seeded at 20e30% conﬂuence and
harvested when cell density reached 90%. A total amount of 850 mg
of soluble proteins in the sample buffer was loaded onto 24-cm IPG
strips (GE Healthcare), with non-linear (NL) pH 3e11 gradient.
Focusing of proteins, equilibration and the 12.5% SDS-PAGE for the
second dimension were performed as previously described (Jami
et al., 2010b). Brieﬂy, Proteins were focused at 20 C according to
the following program: 1 h, 0 V and 12 h, 30 V (rehydration); 30-
min gradient to 10,000 V; up to 9 h, 10,000 V until 85 kV-h. Gels
were stained with Colloidal Coomassie (CC) following the “blue
silver” staining method (Jami et al., 2010a), (Candiano et al., 2004).
2.5. Analysis of differential protein abundance
Two-dimensional images were captured by scanning, digita-
lizing and analysing stained gels as described previously (García-
Estrada et al., 2013). Brieﬂy, images were captured using an Im-
age Scanner II (GE Healthcare) previously calibrated by using a gray
scale marker (Eastman Kodak Co.), digitalized with Labscan 5.00
(v1.0.8) software (GE Healthcare), and analyzed with the Image
Master TM 2D Platinum V7.0 software (GE Healthcare). Three gels
for each condition, obtained from three independent cultures
(biological replicates), were analysed to guarantee representative
results. Differentially expressed proteins between two conditions
were considered when the ratio of the relative volume average for
one speciﬁc spot (present in the three biological replicates) was
higher than 1.5 and the p-value was <0.05. False discovery rate
(FDR) correction for multiple hypothesis testing was performed
according to Storey's method (q-value< 0.05) (Storey, 2002).
2.6. Protein identiﬁcation by mass spectrometry
The protein spots of interest were manually excised from the gel
and washed three times with ammonium bicarbonate/acetonitrile
1:1 (vol/vol) solution. Polyacrylamide fragments were dehydrated
in acetonitrile and dried with a vacuum concentrator. Protein
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acrylamide fragments in 25 mM ammonium carbonate containing
0.15 mg/ml DTT at 56 C. This solution was replaced by 25 mM
ammonium bicarbonate containing 10 mg/ml 2-iodoacetamide
(Bio-Rad) for 45 min at room temperature and in the dark. Frag-
ments were dried as described above and tryptic cleavage was
initiated by reswelling the gel in 25 mM ammonium bicarbonate
containing 0.2 mg trypsin per gel slice (Promega, WI, USA) for
20 min on ice. The solution was then replaced by 25 mM ammo-
nium carbonate and digestion carried out overnight at 37 C.
Tryptic peptides were extracted at 37 C for 15 minwith a 50% (vol/
vol) acetonitrile and 10% (vol/vol) acetic acid solution. A second
extraction was performed under the same conditions. A third
extraction was performed at room temperature for 15 min with
100% acetonitrile. The pooled solutionwas dried under vacuum and
resuspended in 10 ml 0.1% (vol/vol) formic acid as described pre-
viously (Kosalkova et al., 2012) with some modiﬁcations.
Five microliters of each sample were loaded onto a
75 mm  15 cm column self-packed with 3 mm ReproSil-Pur C18-
AQ beads (Dr. Maisch GmbH, Germany). Peptides were eluted
with a gradient of 3e30% acetonitrile in 0.1% formic acid over
60 min at a ﬂow rate of 250 nL/min at 45 C using a Thermo Sci-
entiﬁc EASY-nLC 1000 coupled to a Q Exactive mass spectrometer
(Thermo Fisher Scientiﬁc). The Q Exactive was operated in data-
dependent analysis mode with survey scans acquired at a reso-
lution of 70,000. Up to the top 10 most abundant precursors from
the survey scan were selected with an isolation window of 1.6
Thompsons and fragmented by higher-energy collisional dissoci-
ation with normalized collision energies of 27. The maximum ion
injection times for the survey scan and the MS/MS scans were
20 ms and 60 ms, respectively, and the ion target value for the
survey scan and the MS/MS scans was set to 3,000,000 and
1,000,000, respectively. The raw ﬁles were processed using the
MaxQuant (Cox and Mann, 2008) computational proteomics
platform (version 1.2.7.0) for peptide identiﬁcation and quantita-
tion. The fragmentation spectra were searched against the UniProt
human protein database (downloaded June 27, 2014) containing
87,938 protein sequences and allowing up to two missed tryptic
cleavages. Carbamidomethylation of cysteine was set as a ﬁxed
modiﬁcation and oxidation of methionine and protein N-terminal
acetylation were used as variable modiﬁcations for database
searching. The precursor and fragment mass tolerances were set
to 7 and 20 ppm, respectively. Both peptide and protein identiﬁ-
cations were ﬁltered at 1% false discovery rate (FDR) and thus
were not dependent on the peptide score.
3. Results and discussion
3.1. Treatment conditions
To gain insight into the mechanism by which Edaravone in-
ﬂuences the toxic effects of H2O2 in neuronal cells we performed
three simultaneous treatments (each one in three biological repli-
cates) on dopaminergic SH-SY5Y neuroblastoma cells and analyzed
their proteomic proﬁles under four conditions: Condition 1 (control
condition) contained cells grown in standard culture medium
without treatment, condition 2 contained cells exposed to a toxic
level (2 mM) of H2O2, condition 3 contained cells supplemented
with 25 mM Edaravone, and condition 4 contained cells exposed to
25 mM Edaravone and 2 mM H2O2 simultaneously. Several studies
have demonstrated that Edaravone concentrations, ranging from 1
to 100 mM, has no effect on cell viability (Lee et al., 2010) and
because of this we chose a concentration of 25 mM for our experi-
ments as this concentration resulted in a reversal of H2O2-induced
cytotoxicity (Fig. 1).3.2. Oxidative conditions modify cell morphology, cell integrity, and
apoptosis rate
As shown in Fig. 1 the cell viability and morphology was clearly
altered in response to toxic level of H2O2 in condition 2, however
co-treatment of the culture media with Edaravone and H2O2 (in
condition 4) prevented the viability and morphological changes
(Fig. 1).
Similar results were observed by the Lactate dehydrogenase
(LDH) Cytotoxicity assay that showed a signiﬁcant increase
(p < 0.05) in LDH levels released in the culture media in condition 2
(2.69 fold) and condition 4 (1.34 fold) compared to the control
condition (Fig. 2). This ﬁnding demonstrated a cytotoxic role of
H2O2 and a cytoprotective role for Edaravone as it decreased the
cellular damage rate from 2.69 fold to 1.34.
In addition, TUNEL assays were performed to estimate the
impact of different treatment condition on cell viability and
apoptotic characteristics. These experiments showed averages of
0.84%, 19.38%, 1.32% and 4.83% of apoptotic cells in conditions 1, 2, 3
and 4 respectively (Fig. 3). The results of these experiment indicate
signiﬁcantly increased apoptosis in the presence of H2O2 (condi-
tions 2 and 4) and further that Edaravone causes a signiﬁcant
decrease in apoptosis from 19.38% in condition 2e4.83% in condi-
tion 4.
3.3. Oxidative conditions affect the proteomic proﬁle
The ﬁrst set of proteomic analyses (condition 1 vs. condition 2)
focused on the effects of H2O2, whereinwe compared the proteome
proﬁle of SH-SY5Y cells under control condition (Fig. 4A) to cells
treated with H2O2 (Fig. 4B). In the second set (condition1 vs. con-
dition 3) we analyzed the effects of Edaravone exposure on SH-
SY5Y cells (Fig. 5A) and in the third set (condition1 vs. condition
4) we analyzed the effects of simultaneous exposure to H2O2 and
Edaravone (Fig. 5B). We evaluated the effects of H2O2 treatment on
the cells in three conditions (conditions 1, 2 and 4, Figs. 4A, B and
5B) and observed an up-regulation of 10 proteins (spots1e6 and
10e13) and down-regulation of 6 proteins (7e9 and 14e16)
compared to control condition (Table 1), the same result as we
observed in our previous study (Jami et al., 2014b).
When comparing the proteome proﬁles of cells exposed to
Edaravone (either with or without H2O2) to controls, we observed
up-regulation of spot 17 (in condition 3) and down-regulation of
spot 18 in condition 4. Detailed information on each protein change
are summarized in Table 1 where we classify the differentially
expressed proteins according to their gene ontology (GO, with
focus on biological process) through Uniprot (protein knowledge
website: http://www.uniprot.org/) and QuickGO (http://www.ebi.
ac.uk/QuickGO/). Upon treatments, several biological processes
were affected. For example the majority of protein changes in
response to oxidative stress (conditions 2) belong to the “cell mo-
tion (GO:0006928)” category of proteins, most of which were
prevented by Edaravone co-treatment (condition 4).
3.4. Oxidative stress alters proteins involved in the metabolic routes
to generate higher levels of NADPH
Glutathione is one of the main cellular antioxidants that pre-
vents damage caused by ROS (Pompella et al., 2003). During the
conversion of reactive H2O2 into H2O the reduced form of gluta-
thione is oxidized by glutathione peroxidase. Then glutathione
reductase and NADPH are required to reduce the oxidized gluta-
thione back to its reduced form. Similar to our ﬁndings in our
previous study, neurons seem to respond to the oxidative stress by
generation of higher levels of NADPH (Jami et al., 2014b). Onemajor
Fig. 1. Morphology of SH-SY5Y cells during treatments. SH-SY5Y cells have normal morphology in both condition 1 (without treatment) and condition 3 (treatment with 25 mM
Edaravone for 8 h). Cellular morphology is altered in response to treatment 2 (2 mM H2O2 for 8 h). Normal cellular morphology is maintained in condition 4 (2 mM H2O2 and 25 mM
Edaravone for 8 h).
Fig. 2. Lactate dehydrogenase (LDH) Cytotoxicity assay. Cellular damage following
each treatment condition was assessed by measurement of LDH released into the
medium solution. The average LDH release values obtained from the control condition
was set to 100% and the relative LDH release levels for each treatment condition was
compared to the control condition. LDH levels released in the culture media signiﬁ-
cantly increased (p < 0.05) in condition 2 (2.69 fold) and condition 4 (1.34 fold).
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3-phosphate dehydrogenase (GAPDH). This alteration can result in
a metabolic ﬂux change from glycolysis to the pentose phosphate
pathway (PPP) (Ralser et al., 2007: Jami et al., 2014a). PPP allows
cells to produce higher levels of NADPH to overcome the oxidative
conditions and prevent damage caused by ROS (Pompella et al.,
2003).
We also observed that lactate dehydrogenase (LDH), involved in
oxidation-reduction is up-regulated, a ﬁnding that is in concor-
dance with the results of our LDH cytotoxicity assay. As a cytosolic
enzyme, LDH catalyzes the conversion of pyruvate to lactate inthe absence of oxygen, however it can also perform the reverse
reaction in oxidative conditions and generate NADH (Markert,
1984).
We detected a marked up-regulation of mitochondrial
nucleoside-diphosphate kinase and fumarate hydratase, both
involved in the tricarboxylic acid (TCA) cycle that generates NADH
(convertible to NADPH via nicotinomide nucleotide trans-
hydrogenase (NNT)). Our analysis also showed up-regulation of 3-
Hydroxyacyl CoA dehydrogenase, an oxidoreductase enzyme
involved in beta-oxidation of fatty acids, catalyzing the oxidation of
L-3-hydroxyacyl CoA by NADþ thus generating NADH in response
to oxidative stress (Table 1).
3.5. Cell survival mechanisms are activated in response to oxidative
conditions
In all of the oxidative stress conditions tested we observed
down-regulation of Cathepsin X and Cyclophilin D (both involved
in cell death) and up-regulation of three stress sensor proteins
(Table 1): Annexin A1, Peroxiredoxin-6 and PARK7/DJ-1. All of these
three proteins are involved in cell survival; Annexin A1 can directly
improve cell survival by limiting excessive levels of ROS during
oxidative stress (Gorecka et al., 2005), Peroxiredoxin-6 can reduce
H2O2, short chain fatty acids and phospholipid hydroperoxides
(Fisher, 2011) and PARK7/DJ-1 is involved in protecting cells against
oxidative stress and cell death (Ariga et al., 2013).
3.6. Oxidative conditions affect proteins responsible for cell
integrity
We observed cell morphology modiﬁcation (Fig. 1) and signiﬁ-
cant cell damage (Fig. 2) in condition 2 containing toxic level of
H2O2 mostly in the absence of Edaravone. Interestingly, the
Fig. 3. Evaluation of apoptosis using the TUNEL assay. The different images illustrate representative zones from each condition stained by DAPI, TUNEL. The merged images are also
shown. The average percentage of TUNEL positive cells from 10 different zones in each treatment condition was 0.84%, 19.38%, 1.32% and 4.83% in conditions 1, 2, 3 and 4
respectively.
Fig. 4. Comparison of the proteomes of SH-SY5Y cells with or without H2O2. Representative 2-DE gels (n ¼ 3 for each treatment) of the proteomes of SH-SY5Y cells grown for 8 h in
the absence (A) or presence (B) of 2 mM H2O2. Protein spots showing differential abundance between the two conditions are numbered and correspond to the proteins listed in
Table 1.
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of the cytoskeleton due to oxidative stress. For instance, while all
three members of the ADF/coﬁlin family, including Coﬁlin-1 and
Coﬁlin-2 (which control actin polymerization/depolymerization in
a pH-sensitive manner (Bravo-Cordero et al., 2013)) and Destrin (an
actin depolymerizing factor) are up-regulated, other actin binding
proteins, such as Tropomyosin alpha-4 chain and Tropomyosin
alpha-1 chain are down-regulated (Table 1). These proteins bind to
actin ﬁlaments in muscle and non-muscle cells and play a central
role in muscle contraction and in stabilizing cytoskeleton actin
ﬁlaments in non-muscle cells (Lin et al., 2008).Down-regulation of Vimentin, that is responsible for maintain-
ing cell shape, cytoplasmic integrity, and stabilization of cytoskel-
etal interactions, is also interesting (Table 1). This protein is known
to play a pivotal role in anchoring organelles in the cytosol
(Goldman et al., 1996; Katsumoto et al., 1990). It is possible there-
fore that the observed neuronal morphological changes in response
to H2O2, are due to the attenuation of Vimentin.
3.7. Cytotoxic effects of oxidative stress is reversed by Edaravone
Our proteomic analyses show that the alteration of three
Fig. 5. Proteomes of SH-SY5Y cells exposed to Edaravone with or without H2O2. Representative 2-DE gels (n ¼ 3 for each treatment) of the proteomes of SH-SY5Y cells grown in
media containing 25 mM Edaravone for 8 h in the absence (A) or presence (B) of 2 mM H2O2. Protein spots showing differential abundance between the two conditions are
numbered and correspond to the proteins listed in Table 1.
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hydratase, nucleoside-diphosphate kinase and 3-Hydroxyacyl CoA
dehydrogenase) is maintained at baseline in response to Edaravone
co-treatments (Table 1). Furthermore, we observed the ability of
Edaravone in preventing the toxic effects of H2O2 on cellular
integrity (Figs. 1 and 2). This is in concert with our proteomic re-
sults indicating that Edaravone co-treatments maintained the
expression levels of spots 3, 4, 5, 7, 8 and 9 (the H2O2-induced
protein alterations affecting the cytoskeleton) at baseline (Figs. 4
and 5, Table 1) and is also similar to the results of our previous
study where we observed cytoprotective effects of L-Dopa against
oxidative stress (Jami et al., 2014b).
3.8. Edaravone protects against oxidative stress through
Peroxiredoxin-2
Edaravone treatment resulted in a large increase in the levels
of Peroxiredoxin-2 (PRX2, spot 17 with an average of 12.69 fold
overexpression) (Table 1). Interestingly, the largest increase in
PRX2 is observed in response to Edaravone treatment (conditions
3) whilst the PRX2 induction (5.88 fold), although higher than
control conditions, decreases in response to simultaneous Edar-
avone and H2O2 treatment (condition 4) (Fig. 5). This ﬁnding
suggests that Edaravone scavenges H2O2 via induction of PRX2
and that PRX2 may be degraded during oxidative stress
condition.
Peroxiredoxins (PRXs) represent one of the ROS management
systems that maintain the intracellular reducing environment via
redox reactions at certain cysteine residues. Among them, PRX2
levels are known to be signiﬁcantly elevated in the substantia nigra
of PD patients (Basso et al., 2004). Since PRX2 is the most abundant
PRX enzyme in mammalian neurons (Jin et al., 2005), PRX2 is
considered a vital PRX in DA neuronal survival protecting cells
against oxidative stress (Stresing et al., 2013). It has been docu-
mented that PRX2 is inactivated by hyperoxidation during the
elimination of peroxides (Peskin et al., 2013).
PRX2 is also known to protect cells against oxidative dopami-
nergic neurodegeneration via attenuation of the apoptosis signal-
regulating kinase (ASK1) signaling cascade; this protein inhibitsASK1 activity and the subsequent activation of JNK/c-Jun and
p38 cell death pathways (Hu et al., 2011).
The catalytic breakdown of H2O2 by typical 2-Cys PRXs is
conducted by oxidation of the peroxide-reactive peroxidatic
cysteine followed by the formation of a disulﬁde with the
resolving cysteine of a neighboring PRX molecule (Day et al.,
2012). Thioredoxin then reduces this disulﬁde to restore the
active peroxidase. In addition to its role in the catalytic cycle of
PRX, thioredoxin is a cofactor for many other enzymes and its
oxidoreductase activity is important for reduction of protein
disulﬁdes under oxidative stress conditions (Day et al., 2012).
Interestingly, in our proteomic analyses we observed that the
protein disulﬁde-isomerase A3 or PDIA3 protein is down-
regulated (spot 18, 0.28 fold) upon co-treatment of cells with
Edaravone and H2O2 (Table 1). The PDIA3 protein belongs to the
protein disulﬁde isomerase family and catalyzes the rearrange-
ment of -S-S- bonds in proteins (Bourdi et al., 1995). Our bioin-
formatics analysis using BioGraph online software (http://
biograph.be/)(Liekens et al., 2011) revealed that this protein
contains 2 thioredoxin domains and can therefore participate in
redox regulation through the thioredoxin/peroxiredoxin system.
Moreover, it has been reported that inhibition of PDIA3, as a pro-
apoptotic protein that catalyzes isomerization, reduction, and
oxidation of disulﬁdes, can suppress apoptosis suggesting
increased neuronal survival (Hoffstrom et al., 2010).
This knowledge combined with our experimental ﬁndings
suggests that Edaravone protects neuronal cells against oxidative
stress either by inhibition of apoptosis or more speciﬁcally via
direct induction of PRX2. The exact mechanism of Edaravone-
mediated neuroprotection warrants further investigation as Edar-
avone may not only be a potent neuroprotective agent following
acute brain ischemia, but also as a component of future combina-
torial PD therapeutic strategies. In our previous study we showed
that L-Dopa reverses the H2O2-mediated effects at the cell
morphology and viability level via indirect induction of the ORP150
protein. Since conversion of L-Dopa to norepinephrine requires
molecular oxygen, the exposure to L-Dopa may aid hypoxia condi-
tion in cells and therefore induction of ORP150 with its concomi-
tant cytoprotective effects (Jami et al., 2014b).
Table 1
Detailed information on altered spots during treatment conditions. Differentially expressed proteins (fold-change higher than 1.5 and p-value < 0.05) were classiﬁed according
to their gene ontology (GO). Several biological processes were affected.
Spot ID Protein
ID





p-value q-value GO (biological process)
1 P07954 Fumarate hydratase, mitochondrial 54714 8.85 408 27.2 7.49 3.30E-03 1.42E-04 GO:0009056~catabolic process,
GO:0042592~homeostatic process
2 Q16836 Hydroxyacyl-coenzyme A
dehydrogenase
34613 8.76 118 21.5 5.1 4.52E-03 1.48E-03 GO:0055114~oxidation reduction
3 Q9Y281 Coﬁlin-2 18764 7.66 113 33.1 7.1 8.17E-04 1.63E-03 GO:0030042~actin ﬁlament
depolymerization
4 P60981 Destrin 18852 8.14 147 26.1 4.44 1.33E-04 1.71E-03 GO:0006928~cell motion,
GO:0043243~positive regulation of protein
complex disassembly
5 P23528 Coﬁlin-1 18776 8.22 192 50.6 4.3 2.87E-04 1.86E-03 GO:0006928~cell motion,
GO:0043243~positive regulation of protein
complex disassembly
6 O00746 Nucleoside diphosphate kinase 17469 7.77 1024 41.4 2.7 3.02E-03 2.03E-03 GO:0009116~nucleoside metabolic process
7 Q9BYZ2 L-lactate dehydrogenase A-like 6B 36817 7.62 244 29.6 4.15 1.71E-02 3.82E-03 GO:0055114~oxidation reduction,
GO:0006096~glycolysis
8 P04083 Annexin A1 38816 6.57 142 6.62 2.07 3.78E-03 4.26E-03 GO:00070301~cellular response to
hydrogen proxide,
GO:0006954~inﬂammatory response
9 Q99497 Protein DJ-1 20064 6.33 501 21.2 8.52 7.77E-04 4.15E-03 GO:0006979~response to oxidative stress,
GO:0042592~homeostatic process
10 P30041 Peroxiredoxin-6 25109 5.74 348 35.7 11.3 3.10E-04 4.95E-03 GO:0009056~catabolic process,
GO:0055114~oxidation reduction
11 P08670 Vimentin 53754 5.06 1536 62.2 0.22 2.93E-03 5.00E-03 GO:0006928~cell motion
12 P67936 Tropomyosin alpha-4 chain 28620 4.65 138 23.8 0.16 1.74E-02 5.16E-03 GO:0006928~cell motion





35953 8.49 1165 48.6 0.17 6.76E-03 7.39E-03 GO:0055114~oxidation reduction,
GO:0006096~glycolysis, GO:0006928~cell
motion
15 Q9UBR2 Cathepsin Z 34658 6.13 308 15.7 0.15 8.00E-03 7.92E-03 GO:0006508~proteolysis
16 Q08752 Peptidyl-prolyl cis-trans isomerase
D
20436 6.77 139 8.88 0.12 3.38E-04 8.38E-03 GO:0043065~positive regulation of
apoptotic process




18 P30101 Protein disulﬁde-isomerase A3 57099 6.88 1573 52.7 0.28 3.38E-03 9.43E-03 GO:0042592~homeostatic process,
GO:0046907~intracellular transport
M.-S. Jami et al. / Neurochemistry International 90 (2015) 134e1411404. Conclusions
Free radicals are important targets for therapeutic intervention
of neurodegenerative diseases as oxidative stress represents an
important factor. As a free radical scavenger, Edaravone may offer a
novel treatment option for neurodegeneration. Using a 2DE-based
proteomic study we have shown that oxidative stress changes
neuronal metabolic routes and affects cytoskeletal integrity in
neuroblastoma cells. As observedwith L-Dopa in our previous study
we show here that Edaravone reverses H2O2-mediated effects at
the protein level. However, the cytoprotective effects of these two
compounds appear to inﬂuence different pathways. L-Dopa seems
to aid hypoxia condition in cells and therefore induction of ORP150
with its concomitant cytoprotective effects whilst Edaravone pro-
tect neuronal cells against oxidative stress via direct induction of
PRX2 and inhibition of apoptosis.
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